"Pyrimidines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
| Descriptor ID |
D011743
|
| MeSH Number(s) |
D03.383.742
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrimidines".
Below are MeSH descriptors whose meaning is more specific than "Pyrimidines".
This graph shows the total number of publications written about "Pyrimidines" by people in this website by year, and whether "Pyrimidines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 3 | 2 | 5 |
| 2006 | 1 | 0 | 1 |
| 2008 | 3 | 3 | 6 |
| 2009 | 1 | 3 | 4 |
| 2010 | 4 | 1 | 5 |
| 2011 | 2 | 0 | 2 |
| 2012 | 7 | 1 | 8 |
| 2013 | 3 | 2 | 5 |
| 2014 | 7 | 0 | 7 |
| 2015 | 4 | 0 | 4 |
| 2016 | 2 | 1 | 3 |
| 2017 | 2 | 2 | 4 |
| 2018 | 3 | 1 | 4 |
| 2019 | 1 | 2 | 3 |
| 2020 | 2 | 4 | 6 |
| 2021 | 4 | 1 | 5 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyrimidines" by people in Profiles.
-
Cullin neddylation inhibitor attenuates hyperglycemia by enhancing hepatic insulin signaling through insulin receptor substrate stabilization. Proc Natl Acad Sci U S A. 2022 02 08; 119(6).
-
Milvexian for the Prevention of Venous Thromboembolism. N Engl J Med. 2021 12 02; 385(23):2161-2172.
-
Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study. Int J Cancer. 2021 07 15; 149(2):403-408.
-
Novel pyrazolo[4,3-d]pyrimidine microtubule targeting agents (MTAs): Synthesis, structure-activity relationship, in vitro and in vivo evaluation as antitumor agents. Bioorg Med Chem Lett. 2021 06 01; 41:127923.
-
Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer. Cancer Chemother Pharmacol. 2021 05; 87(5):689-700.
-
Serotonin Pathway in Cancer. Int J Mol Sci. 2021 Jan 28; 22(3).
-
The 3-D conformational shape of N-naphthyl-cyclopenta[d]pyrimidines affects their potency as microtubule targeting agents and their antitumor activity. Bioorg Med Chem. 2021 01 01; 29:115887.
-
Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations. Ann Oncol. 2021 02; 32(2):261-268.
-
Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study. Adv Ther. 2021 01; 38(1):350-365.
-
Pulmonary Artery Denervation for Patients With Residual Pulmonary Hypertension After Pulmonary Endarterectomy. J Am Coll Cardiol. 2020 08 25; 76(8):916-926.